ATTENTION MYGN SHAREHOLDERS: Investors who lost money on Myriad Genetics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
Portfolio Pulse from
Levi & Korsinsky has initiated an investigation into Myriad Genetics, Inc. for potential violations of federal securities laws. This follows UnitedHealth Group's decision to stop covering Myriad's GeneSight test starting January 1, 2025.
November 07, 2024 | 3:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Myriad Genetics is under investigation for potential securities law violations after UnitedHealth announced it will stop covering GeneSight, a key product, from January 2025.
The investigation into Myriad Genetics for potential securities law violations, combined with the loss of coverage for GeneSight by UnitedHealth, could negatively impact investor confidence and the company's stock price. GeneSight is a significant product for Myriad, and losing coverage from a major insurer like UnitedHealth could lead to reduced revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100